acquisition
Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash
December 3, 2019Manufacturing and Production, Sales and Marketing Astellas, Audentes, acquisition, neuromuscular disease, pharma
Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …
MSD scoops up biopharma firm Tilos for $773 million
June 10, 2019Sales and Marketing MSD, Tilos Therapeutics, acquisition, pharma
US-based firm MSD has announced it intends to acquire biopharma firm Tilos Therapeutics, and has signed a deal with the …
MSD buys Peloton Therapeutics in deal worth $2.1 billion
May 22, 2019Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma
MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …
Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar
March 4, 2019Sales and Marketing Biogen, Nightstar, acquisition, pharma
Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of …
Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt
February 28, 2019Sales and Marketing Bristol-Myers Squibb, Celgene, acquisition, pharma
The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, …
Ipsen shells out $1.31bn to acquire rare disease specialist Clementia Pharmaceuticals
February 25, 2019Sales and Marketing Clementia pharmaceuticals, acquisition, ipsen, rare disease
In a bid to boost its rare disease portfolio prospects, Ipsen has revealed its intention to acquire Clementia Pharmaceuticals, with …
Roche set to acquire Spark Therapeutics in $4.8 billion deal
February 25, 2019Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma
Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …
Takeda completes Shire acquisition
January 8, 2019Manufacturing and Production M&A, MA, Shire, Takeda, acquisition, deal, pharma
Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm …
AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T
January 8, 2019Manufacturing and Production AbbVie, M&A, MA, Stemcentrx, acquisition, rova-t
US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment …
BMS to acquire Celgene for $74 billion in biggest-ever pharma deal
January 4, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, acquisition, pharma
Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of …
Takeda shareholders approve $62bn Shire acquisition
December 6, 2018Business Services Ireland, Japan, M&A, MA, Shire, Takeda, acquisition
Japanese firm Takeda have gained shareholders’ approval for the $62 billion acquisition of the Irish headquartered company Shire Plc. The …
GSK to acquire oncology biotech Tesaro for $5.1 billion
December 3, 2018Sales and Marketing GSK, GlaxoSmtihKline, Tesaro, acquisition, oncology, pharma
GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash …
Novartis denies potential split with Sandoz
November 15, 2018Business Services, Manufacturing and Production Business, M&A, MA, Novartis, Sandoz, acquisition, mergers
Swiss newspaper Tages-Anzeiger has reported that Novartis is preparing for a split with long-term partner Sandoz. The two companies merged …
Allergan acquires neurotoxin specialist Bonti in $195m deal
September 17, 2018Sales and Marketing Allergan, Bonti, Botox, Neurotoxin, acquisition, deal
The Dublin-headquartered multinational Allergan have agreed to acquire the clinical stage biotech Bonti in a deal worth more than $195 …
Otsuka snaps up Visterra in $430 million deal
July 12, 2018Research and Development, Sales and Marketing Otsuka, Visterra, acquisition, pharma
Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
